Where the traps are

Most of this market is not dishonest. It is structured — and the structure reliably produces a second statement larger than the first. Here is where that happens most.

The widest advertised-to-billed gap on our tirzepatide board is Ro, at $299 a month between the headline and the charge. The highest outright price is Henry Meds at $449 a month.

Biggest gaps between advert and bill

Highest prices on the board

1. Henry Meds — $449/mo

Two to report. A $50 step between month one and month two, and a $270 spread between the advertised entry tier and the injection most readers are shopping for. Neither is concealed; both are easy to misread.

Full review.

2. Ro — $448/mo

The gap here is not a hidden fee — Ro is clear that medication is separate. The gap is between what people assume a $39 first month buys and what it actually buys, which is one month of membership and no drug at all.

Full review.

3. Remedy Meds — $399/mo

$120 between the first month and the renewal. Disclosed, but it is the figure people budget from and then get wrong.

Full review.

4. Willow — $399/mo

No fee gap to report. What is missing is information: which pharmacy fills it, whether that is a 503A or 503B facility, and how dose changes are reviewed are all unpublished.

Full review.

The three we would flag hardest

1. The $99 that is $198. Eden advertises $99 semaglutide with a membership that renews at $99. Another programme advertises the same $99 and charges nothing on top.
2. The $349 that is $399. TrimRx advertises $349 and has been reported billing $399 on ongoing terms — read the payment screen.
3. The $179 that is $297. Henry Meds advertises from $179, which is the sublingual tier, not the weekly injection at $297.

None of that is illegal. All of it is avoidable if you ask one question: what will I be charged on my second statement? The cheap end of the board is in cheapest right now.